Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M B Atkins

Showing results (1-10 of 101) with videos related to

Pageof 11
Sort By:
The Cancer Journal From Scientific American|March 1, 1996
Interleukin-2 therapy: a decade of slow but steady progressM B Atkins
The Cancer Journal From Scientific American|February 11, 1998
Interleukin-2 in metastatic melanoma: establishing a roleM B Atkins
Hematology/Oncology Clinics of North America|October 6, 1998
Immunotherapy and experimental approaches for metastatic melanomaM B Atkins
The Cancer Journal From Scientific American|February 24, 2000
Interleukin-2 in metastatic melanoma: what is the current role?M B Atkins
Current Opinion in Oncology|March 1, 1997
The treatment of metastatic melanoma with chemotherapy and biologicsM B Atkins
Clinical Pharmacology and Therapeutics|October 2, 2013
Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapiesS Jang, M B Atkins
The New England Journal of Medicine|March 13, 1997
Renal-cell carcinomaM B Atkins, J P Dutcher
Cancer|July 15, 1996
Adoptive immunotherapy for nonsmall cell lung carcinoma. A fourth treatment modality, complicated radiation sensitizer, or none of the aboveD D Karp, M B Atkins
Current Opinion in Investigational Drugs (London, England : 2000)|January 5, 2002
Immunotherapeutic approaches for the treatment of malignant melanomaC Curiel-Lewandrowski, M B Atkins
Current Opinion in Oncology|November 1, 1993
Mechanisms of action and toxicity of immunotherapy with cytokinesJ W Mier, M B Atkins
Pageof 11

Showing results (1-10 of 101) with videos related to

Sort By:
Pageof 11
The Cancer Journal From Scientific American|March 1, 1996
Interleukin-2 therapy: a decade of slow but steady progressM B Atkins
The Cancer Journal From Scientific American|February 11, 1998
Interleukin-2 in metastatic melanoma: establishing a roleM B Atkins
Hematology/Oncology Clinics of North America|October 6, 1998
Immunotherapy and experimental approaches for metastatic melanomaM B Atkins
The Cancer Journal From Scientific American|February 24, 2000
Interleukin-2 in metastatic melanoma: what is the current role?M B Atkins
Current Opinion in Oncology|March 1, 1997
The treatment of metastatic melanoma with chemotherapy and biologicsM B Atkins
Clinical Pharmacology and Therapeutics|October 2, 2013
Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapiesS Jang, M B Atkins
The New England Journal of Medicine|March 13, 1997
Renal-cell carcinomaM B Atkins, J P Dutcher
Cancer|July 15, 1996
Adoptive immunotherapy for nonsmall cell lung carcinoma. A fourth treatment modality, complicated radiation sensitizer, or none of the aboveD D Karp, M B Atkins
Current Opinion in Investigational Drugs (London, England : 2000)|January 5, 2002
Immunotherapeutic approaches for the treatment of malignant melanomaC Curiel-Lewandrowski, M B Atkins
Current Opinion in Oncology|November 1, 1993
Mechanisms of action and toxicity of immunotherapy with cytokinesJ W Mier, M B Atkins
Pageof 11